References
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease2018 Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfAccessed September 25, 2018
- CalverleyPMRabeKFGoehringUMRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
- FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
- MartinezFJRabeKFSethiSEffect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical TrialAm J Respir Crit Care Med2016194555956727585384
- AgustiAEdwardsLDCelliBCharacteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohortEur Respir J201342363664623766334
- VillettiGCarniniCBattipagliaLCHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration – in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic windowJ Pharmacol Exp Ther2015352356857825576073
- MorettoNCarusoPBoscoRCHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administrationJ Pharmacol Exp Ther2015352355956725576075
- EdwardsMRFacchinettiFCivelliMVillettiGJohnstonSLAnti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokinesPharmacol Res Perspect201641e0020226977295
- ArmaniEAmariGRizziANovel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseasesJ Med Chem201457379381624400806
- CenacchiVBattagliaRCinatoFIn vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitorXenobiotica201545869371025733029